Does Rallies show Form 4 insider transactions for HROW?

Yes. Rallies tracks HROW insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HROW research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HROW. It does not provide personalized investment advice.

HROW (Harrow, Inc. Common Stock) Stock Analysis - Insider Trades

Harrow, Inc. Common Stock (HROW) is a publicly traded Healthcare sector company. As of May 21, 2026, HROW trades at $30.57 with a market cap of $1.15B and a P/E ratio of -79.81. HROW moved +0.88% today. Year to date, HROW is -43.69%; over the trailing twelve months it is +9.94%. Its 52-week range spans $20.85 to $59.23. Analyst consensus is strong buy with an average price target of $67.17. Rallies surfaces HROW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HROW stock inside the company?

Recent HROW insider activity includes Graves Adrienne L bought 1.00K, SILVERNAIL LAUREN P bought 1.00K, BAUM MARK L bought 10.00K, BOLL ANDREW R. bought 3.50K, and Opaleye Management Inc. sold 134.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HROW Key Metrics

Key financial metrics for HROW
Metric	Value
Price	$30.57
Market Cap	$1.15B
P/E Ratio	-79.81
EPS	$-0.39
Dividend Yield	0.00%
52-Week High	$59.23
52-Week Low	$20.85
Volume	181
Avg Volume	0
Revenue (TTM)	$268.68M
Net Income	$-14.96M
Gross Margin	74.11%

Recent HROW Insider Trades

Graves Adrienne L bought 1.00K (~$31.07K) on May 18, 2026.
SILVERNAIL LAUREN P bought 1.00K (~$31.00K) on May 18, 2026.
BAUM MARK L bought 10.00K (~$302.00K) on May 14, 2026.
BOLL ANDREW R. bought 3.50K (~$104.65K) on May 14, 2026.
Opaleye Management Inc. sold 134.00K (~$5.32M) on Mar 4, 2026.

Latest HROW News

Harrow Q1 Revenue Hit by VEVYE Coverage Gap and High-Deductible Patients — May 12, 2026
Harrow Q1 Revenue $44.2M with Record VEVYE Prescriptions, Upholds $365M Guidance — May 11, 2026
Harrow Secures LogiCare3PL Partner; Analyst Sees 104% Upside to $73.25 Fair Value — Apr 14, 2026
Harrow Health Maintains Buy Rating, Submits 3 Abstracts to ASCRS Meeting — Mar 24, 2026
Harrow Earns Three ASCRS 2026 Presentations on VEVYE 0.1% and ILEVRO 0.3% Data — Mar 18, 2026

HROW Analyst Consensus

8 analysts cover HROW: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $67.17.

Common questions about HROW

Who is trading HROW stock inside the company?: Recent HROW insider activity includes Graves Adrienne L bought 1.00K, SILVERNAIL LAUREN P bought 1.00K, BAUM MARK L bought 10.00K, BOLL ANDREW R. bought 3.50K, and Opaleye Management Inc. sold 134.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HROW?: Yes. Rallies tracks HROW insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HROW research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HROW. It does not provide personalized investment advice.